Sepul Bio, a business unit of Laboratoires Théa, Doses First Participant in Phase 2b Clinical Trial of ultevursen for USH2A-associated retinitis pigmentosa
Sepul Bio, an innovative business unit of Laboratoires Théa (“Théa”)dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the first clinical participant has been dosed in LUNA clinical study, a Phase 2b clinical study for ultevursen, in individuals with retinitis pigmentosa (RP) or non-syndromic RP due to variants in exon […]
Continue Reading